Ying Ou1, Yang Xu2, Lia Gore3, R Donald Harvey4, Alain Mita5, Kyriakos P Papadopoulos6, Zhengping Wang1, Richard E Cutler7, Dawn E Pinchasik1, Apostolia M Tsimberidou8. 1. Amgen Inc., South San Francisco, CA, USA. 2. Amgen Inc., Thousand Oaks, CA, USA. 3. University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 4. Winship Cancer Institute of Emory University, Atlanta, GA, USA. 5. Cedars-Sinai Medical Center, Los Angeles, CA, USA. 6. South Texas Accelerated Research Therapeutics, San Antonio, TX, USA. 7. Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA. 8. University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
AIMS: Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. Oprozomib is a rare example of a small molecule drug that demonstrates cytochrome P450 (CYP) mRNA suppression. This unusual property elicits uncertainty regarding the optimal approach for predicting its drug-drug interaction (DDI) risk. The current study aims to understand DDI potential during early clinical development of oprozomib. METHODS: To support early development of oprozomib (e.g. inclusion/exclusion criteria, combination study design), we used human hepatocyte data and physiologically-based pharmacokinetic (PBPK) modelling to predict its CYP3A4-mediated DDI potential. Subsequently, a clinical DDI study using midazolam as the substrate was conducted in patients with advanced malignancies. RESULTS: The clinical DDI study enrolled a total of 21 patients, 18 with advanced solid tumours. No patient discontinued oprozomib due to a treatment-related adverse event. The PBPK model prospectively predicted oprozomib 300 mg would not cause a clinically relevant change in exposure to CYP3A4 substrates (≤30%), which was confirmed by the results of this clinical DDI study. CONCLUSIONS: These results indicate oprozomib has a low potential to inhibit the metabolism of CYP3A4 substrates in humans. The study shows that cultured human hepatocytes are a more reliable system for DDI prediction than human liver microsomes for studying this class of compounds. Developing a PBPK model prior to a clinical DDI study has been valuable in supporting clinical development of oprozomib.
AIMS: Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. Oprozomib is a rare example of a small molecule drug that demonstrates cytochrome P450 (CYP) mRNA suppression. This unusual property elicits uncertainty regarding the optimal approach for predicting its drug-drug interaction (DDI) risk. The current study aims to understand DDI potential during early clinical development of oprozomib. METHODS: To support early development of oprozomib (e.g. inclusion/exclusion criteria, combination study design), we used human hepatocyte data and physiologically-based pharmacokinetic (PBPK) modelling to predict its CYP3A4-mediated DDI potential. Subsequently, a clinical DDI study using midazolam as the substrate was conducted in patients with advanced malignancies. RESULTS: The clinical DDI study enrolled a total of 21 patients, 18 with advanced solid tumours. No patient discontinued oprozomib due to a treatment-related adverse event. The PBPK model prospectively predicted oprozomib 300 mg would not cause a clinically relevant change in exposure to CYP3A4 substrates (≤30%), which was confirmed by the results of this clinical DDI study. CONCLUSIONS: These results indicate oprozomib has a low potential to inhibit the metabolism of CYP3A4 substrates in humans. The study shows that cultured human hepatocytes are a more reliable system for DDI prediction than human liver microsomes for studying this class of compounds. Developing a PBPK model prior to a clinical DDI study has been valuable in supporting clinical development of oprozomib.
Authors: Jeffrey R Infante; David S Mendelson; Howard A Burris; Johanna C Bendell; Anthony W Tolcher; Michael S Gordon; Heidi H Gillenwater; Shirin Arastu-Kapur; Hansen L Wong; Kyriakos P Papadopoulos Journal: Invest New Drugs Date: 2016-02-29 Impact factor: 3.850
Authors: Richard C Zangar; Thomas A Kocarek; Shang Shen; Nikki Bollinger; Michael S Dahn; Donna W Lee Journal: J Pharmacol Exp Ther Date: 2003-03-06 Impact factor: 4.030
Authors: K K Machavaram; L M Almond; A Rostami-Hodjegan; I Gardner; M Jamei; S Tay; S Wong; A Joshi; J R Kenny Journal: Clin Pharmacol Ther Date: 2013-04-10 Impact factor: 6.875
Authors: Han-Jie Zhou; Monette A Aujay; Mark K Bennett; Maya Dajee; Susan D Demo; Ying Fang; Mark N Ho; Jing Jiang; Christopher J Kirk; Guy J Laidig; Evan R Lewis; Yan Lu; Tony Muchamuel; Francesco Parlati; Eileen Ring; Kevin D Shenk; Jamie Shields; Peter J Shwonek; Timothy Stanton; Congcong M Sun; Catherine Sylvain; Tina M Woo; Jinfu Yang Journal: J Med Chem Date: 2009-05-14 Impact factor: 7.446
Authors: Ying Ou; Yang Xu; Lia Gore; R Donald Harvey; Alain Mita; Kyriakos P Papadopoulos; Zhengping Wang; Richard E Cutler; Dawn E Pinchasik; Apostolia M Tsimberidou Journal: Br J Clin Pharmacol Date: 2018-12-25 Impact factor: 4.335
Authors: Robert Shumaker; Min Ren; Jagadeesh Aluri; Corina E Dutcus; Christian Rance; Cixin He Journal: Eur J Drug Metab Pharmacokinet Date: 2020-06 Impact factor: 2.441